These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37963308)

  • 21. Effects of pharmacologic and nonpharmacologic interventions on menopause-related quality of life: a pooled analysis of individual participant data from four MsFLASH trials.
    Diem SJ; LaCroix AZ; Reed SD; Larson JC; Newton KM; Ensrud KE; Woods NF; Guthrie KA
    Menopause; 2020 Oct; 27(10):1126-1136. PubMed ID: 32701665
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
    Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
    Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of fezolinetant on sleep disturbance and impairment during treatment of vasomotor symptoms due to menopause.
    Shapiro C M M; Cano A; Nappi RE; Santoro N; English ML; Mancuso S; Morga A; Siddiqui E; Valluri U; Ottery FD
    Maturitas; 2024 Aug; 186():107999. PubMed ID: 38749864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms.
    Guthrie KA; LaCroix AZ; Ensrud KE; Joffe H; Newton KM; Reed SD; Caan B; Carpenter JS; Cohen LS; Freeman EW; Larson JC; Manson JE; Rexrode K; Skaar TC; Sternfeld B; Anderson GL
    Obstet Gynecol; 2015 Aug; 126(2):413-422. PubMed ID: 26241433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of elinzanetant, a selective neurokinin-1,3 receptor antagonist for vasomotor symptoms: a dose-finding clinical trial (SWITCH-1).
    Simon JA; Anderson RA; Ballantyne E; Bolognese J; Caetano C; Joffe H; Kerr M; Panay N; Seitz C; Seymore S; Trower M; Zuurman L; Pawsey S
    Menopause; 2023 Mar; 30(3):239-246. PubMed ID: 36720081
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic review and network meta-analysis comparing the efficacy of fezolinetant with hormone and nonhormone therapies for treatment of vasomotor symptoms due to menopause.
    Morga A; Ajmera M; Gao E; Patterson-Lomba O; Zhao A; Mancuso S; Siddiqui E; Kagan R
    Menopause; 2024 Jan; 31(1):68-76. PubMed ID: 38016166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women.
    Rahman SA; Nathan MD; Wiley A; Crawford S; Cohn AY; Harder JA; Grant LK; Erickson A; Srivastava A; McCormick K; Bertisch SM; Winkelman JW; Joffe H
    Sleep; 2022 Mar; 45(3):. PubMed ID: 35022783
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vasomotor and depression symptoms may be associated with different sleep disturbance patterns in postmenopausal women.
    Vousoura E; Spyropoulou AC; Koundi KL; Tzavara C; Verdeli H; Paparrigopoulos T; Augoulea A; Lambrinoudaki I; Zervas IM
    Menopause; 2015 Oct; 22(10):1053-7. PubMed ID: 25783470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lights on MsFLASH: a review of contributions.
    Reed SD; LaCroix AZ; Anderson GL; Ensrud KE; Caan B; Carpenter JS; Cohen L; Diem SJ; Freeman EW; Joffe H; Larson JC; McCurry SM; Mitchell CM; Newton KM; Sternfeld B; Guthrie KA
    Menopause; 2020 Apr; 27(4):473-484. PubMed ID: 31977667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationships Between Vasomotor Symptoms and Mood in Midlife Urban Chinese Women: Observations in a Prospective Study.
    Tang R; Luo M; Li J; Peng Y; Wang Y; Liu B; Liu G; Wang Y; Lin S; Chen R
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32841324
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Telephone-Based Cognitive Behavioral Therapy for Insomnia in Perimenopausal and Postmenopausal Women With Vasomotor Symptoms: A MsFLASH Randomized Clinical Trial.
    McCurry SM; Guthrie KA; Morin CM; Woods NF; Landis CA; Ensrud KE; Larson JC; Joffe H; Cohen LS; Hunt JR; Newton KM; Otte JL; Reed SD; Sternfeld B; Tinker LF; LaCroix AZ
    JAMA Intern Med; 2016 Jul; 176(7):913-20. PubMed ID: 27213646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials.
    Cano A; Nappi RE; Santoro N; Stute P; Blogg M; English ML; Morga A; Scrine L; Siddiqui E; Ottery FD
    BJOG; 2024 Aug; 131(9):1296-1305. PubMed ID: 38320967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of the neurokinin 3 receptor antagonist fezolinetant on patient-reported outcomes in postmenopausal women with vasomotor symptoms: results of a randomized, placebo-controlled, double-blind, dose-ranging study (VESTA).
    Santoro N; Waldbaum A; Lederman S; Kroll R; Fraser GL; Lademacher C; Skillern L; Young J; Ramael S
    Menopause; 2020 Dec; 27(12):1350-1356. PubMed ID: 32769757
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Confirmatory factor analysis of the Insomnia Severity Index (ISI) and invariance across race: a pooled analysis of MsFLASH data.
    Otte JL; Bakoyannis G; Rand KL; Ensrud KE; Guthrie KA; Joffe H; McCurry SM; Newton KM; Carpenter JS
    Menopause; 2019 Aug; 26(8):850-855. PubMed ID: 30994570
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT.
    Johnson KA; Martin N; Nappi RE; Neal-Perry G; Shapiro M; Stute P; Thurston RC; Wolfman W; English M; Franklin C; Lee M; Santoro N
    J Clin Endocrinol Metab; 2023 Jul; 108(8):1981-1997. PubMed ID: 36734148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychometric evaluation of the PROMIS SD-SF-8b instrument in individuals experiencing vasomotor symptoms due to menopause.
    Schultz NM; Morga A; Siddiqui E; Rhoten SE
    Health Qual Life Outcomes; 2023 Nov; 21(1):126. PubMed ID: 37990323
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vasomotor Symptoms and Accelerated Epigenetic Aging in the Women's Health Initiative (WHI).
    Thurston RC; Carroll JE; Levine M; Chang Y; Crandall C; Manson JE; Pal L; Hou L; Shadyab AH; Horvath S
    J Clin Endocrinol Metab; 2020 Apr; 105(4):1221-7. PubMed ID: 32080740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validity, cut-points, and minimally important differences for two hot flash-related daily interference scales.
    Carpenter JS; Bakoyannis G; Otte JL; Chen CX; Rand KL; Woods N; Newton K; Joffe H; Manson JE; Freeman EW; Guthrie KA
    Menopause; 2017 Aug; 24(8):877-885. PubMed ID: 28509814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of oral versus transdermal menopausal hormone treatments on self-reported sleep domains and their association with vasomotor symptoms in recently menopausal women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS).
    Cintron D; Lahr BD; Bailey KR; Santoro N; Lloyd R; Manson JE; Neal-Perry G; Pal L; Taylor HS; Wharton W; Naftolin F; Harman SM; Miller VM
    Menopause; 2018 Feb; 25(2):145-153. PubMed ID: 28832429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Menopause Strategies-Finding Lasting Answers for Symptoms and Health (MsFLASH) Investigation of Self-Reported Menopausal Palpitation Distress.
    Carpenter JS; Tisdale JE; Chen CX; Kovacs R; Larson JC; Guthrie KA; Ensrud KE; Newton KM; LaCroix AZ
    J Womens Health (Larchmt); 2021 Apr; 30(4):533-538. PubMed ID: 33217253
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.